cis-3-methylcyclohexyl fluoride | 74185-62-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 英文名称: cis-3-methylcyclohexyl fluoride
• 英文别名: (1R,3S)-1-fluoro-3-methylcyclohexane
• CAS: 74185-62-9
• 化学式: C₇H₁₃F
• 分子量: 116.179
• InChiKey: BJYNDVCWPFJPDJ-NKWVEPMBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-氟甲苯 在 氢气 、 calcium oxide 作用下， 以 正庚烷 为溶剂， 80.0 ℃ 、1.0 MPa 条件下， 反应 1.0h， 以54%的产率得到
  参考文献：
  名称：

  在分子改性的二氧化硅上使用铑纳米粒子对氟化芳烃进行选择性加氢

  摘要：

  氟化环己烷衍生物的生产是通过在分子改性的二氧化硅载体（Rh @ Si–R）上作为高效且可回收的催化剂，使用Rh纳米粒子对易得的氟化芳烃进行选择性氢化来完成的。催化剂制备包括将非极性分子实体接枝在SiO 2表面上，从而产生疏水性环境，以控制从简单的有机金属前体中沉淀出明确的铑颗粒。各种氟化环己烷衍生物被证明具有出色的功效（0.05–0.5 mol％Rh，10–55 bar H 2，80–100°C，1-2小时），包括与工业相关的构建基块。添加CaO作为痕量HF的清除剂可大大提高催化体系的可回收性，并防止与HF存在相关的风险，而不会影响反应的活性和选择性。

  DOI：

  10.1039/d0cy01716g

文献信息

• Compounds for the Treatment of Medical Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20170056428A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.
• Amide Compounds for Treatment of Medical Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20170057950A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an amide substituent (R 32 ) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein are capable of reducing the excessive activation of complement.
• Ether Compounds for Treatment of Medical Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20170057993A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an ether substituent (R 32 ) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.
• Phosphonate Compounds for Treatment of Medical Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20170057983A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is a phosphonate substituent (R 32 ) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.
• Selective hydrogenation of fluorinated arenes using rhodium nanoparticles on molecularly modified silica
  作者：Souha Kacem、Meike Emondts、Alexis Bordet、Walter Leitner

  DOI：10.1039/d0cy01716g

  日期：——

  arenes using Rh nanoparticles on molecularly modified silica supports (Rh@Si–R) as highly effective and recyclable catalysts. The catalyst preparation comprises grafting non-polar molecular entities on the SiO2 surface generating a hydrophobic environment for controlled deposition of well-defined rhodium particles from a simple organometallic precursor. A broad range of fluorinated cyclohexane derivatives

  氟化环己烷衍生物的生产是通过在分子改性的二氧化硅载体（Rh @ Si–R）上作为高效且可回收的催化剂，使用Rh纳米粒子对易得的氟化芳烃进行选择性氢化来完成的。催化剂制备包括将非极性分子实体接枝在SiO 2表面上，从而产生疏水性环境，以控制从简单的有机金属前体中沉淀出明确的铑颗粒。各种氟化环己烷衍生物被证明具有出色的功效（0.05–0.5 mol％Rh，10–55 bar H 2，80–100°C，1-2小时），包括与工业相关的构建基块。添加CaO作为痕量HF的清除剂可大大提高催化体系的可回收性，并防止与HF存在相关的风险，而不会影响反应的活性和选择性。